Sovleplenib
Small molecule
Also known as HMPL-523
Evidence outlook · regulatory review
Immune Thrombocytopenia: application under FDA review
US FDA Orphan Drug Designation for sovleplenib in primary ITP (2026-10-29). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
No registered studies for this indication.
Competitive landscape
This drug's own stage for Immune Thrombocytopenia: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sovleplenib: this drug | Stage not on record | Small molecule | Syk | Reliable signal | NCT05029635: ESLIM-01 (Lancet Haematology 2024): durable response rate 48.4% (sovleplenib) vs 0% (placebo), p<0.0001; overall response rate 70.6% vs 16.1%. | |
| Fostamatinib (Tavalisse) | Approved | Small molecule | Spleen tyrosine kinase (Syk) | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Approved | Small molecule | BTK | Reliable signal | No reviewed efficacy summary in this indication | |
| CID-103 | Phase 2 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent